Tag Archives: Peter Lawson

Exelixis Receives a Buy from SunTrust Robinson

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Exelixis (NASDAQ: EXEL) on December 19 and set a price target of $38. The company’s shares closed yesterday at $27.81. According to TipRanks.com, Lawson is a 4-star analyst with an

SunTrust Robinson Reiterates Their Buy Rating on Adaptimmune Therapeutics

In a report released today, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP), with a price target of $10. The company’s shares closed yesterday at $8.10. According to TipRanks.com, Lawson is a 4-star analyst

Crispr Therapeutics AG Receives a Hold from SunTrust Robinson

SunTrust Robinson analyst Peter Lawson reiterated a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP) on November 9 and set a price target of $16. The company’s shares closed yesterday at $17.45. According to TipRanks.com, Lawson is a 4-star analyst

SunTrust Robinson Thinks Tesaro’s Stock is Going to Recover

In a report issued on November 8, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Tesaro (NASDAQ: TSRO), with a price target of $160. The company’s shares closed yesterday at $91.09, close to its 52-week low of $89.

Array Biopharma Gets a Buy Rating from SunTrust Robinson

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Array Biopharma (NASDAQ: ARRY) yesterday and set a price target of $16. The company’s shares opened today at $10.53. According to TipRanks.com, Lawson is a 5-star analyst with an average

SunTrust Robinson Reiterates a Buy Rating on Adaptimmune Therapeutics

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) on October 9 and set a price target of $10. The company’s shares opened today at $7.88. According to TipRanks.com, Lawson is a 5-star analyst with